Special Interest Groups
A Special Interest Group (SIG) is a group of ISoP members acting as volunteers and working on a specific and relevant topic which is within the scope and aims of ISoP.
Currently there are established SIGs on
‘Women’s medicines’,
‘Risk communication’,
‘Risk Minimisation Methods for Asian countries’,
‘Herbal and Traditional Medicines’,
‘PV Professional Qualification Framework’,
‘Medication Errors’,
‘Vaccine surveillance’
‘Pharmacogenomics’
‘Medical Device Safety’,
‘Patient Engagement’
‘Ecopharmacovigilance’
‘Drug Safety in Older Patients’
‘Real-World Evidence and Big Data Group’.
To explore our Special Interest Groups, please use the green navigation menu.
Guidelines:
Please click the button to the right for the latest SIG guidelines – or contact ISoP Administration for more information.
Women’s Medicine Group
Women, half of our worldwide population, take medicines throughout their lifetime. This SIG focusses on the proper use of medicines, their benefits and harms.
READ MORERisk Communication Group
This SIG deals with all aspects of risk communication as a sub-discipline of safety surveillance and risk mitigation of medicines.
READ MORE
Risk Minimisation Methods for Asian countries
The focus of this SIG will be to elaborate and deliver risk minimization methods and strategies able to fit particularly the needs of countries in Asia.
READ MOREHerbal and Traditional Medicines Group
Exploring issues relating to the safety and Pharmacovigilance of herbal and traditional medicines.
READ MORE
Pharmacovigilance Professional Qualification Framework Group
Responding to the need of harmonisation in professional pharmacovigilance qualifications.
READ MOREMedication Errors
Ensuring the safe and effective use healthcare products is a key objective for all who work in pharmacovigilance, patients and all other stakeholders.
READ MORE
Vaccine Surveillance
Recent years have brought new challenges to the field of vaccine safety surveillance.
READ MOREPharmacogenomics
There is large interindividual variability in drug response. Some of the variation is related to inherited characteristics of the genome. These genomic variations may relate to pharmacokinetics (PK) or pharmacodynamics (PD) or to individual’s susceptibility.
READ MORE
Medical Devices
We have created the Medical Device Safety Special Interest Group to provide a forum for members to share experiences to suggest and discuss best practices and policy in the field of medical device performance monitoring and safety surveillance.
READ MOREPatient Engagement Group
The role of the patient in pharmacovigilance is key. The need for early involvement of the patient in the cycle of drug development is widely recognised, and direct patient reporting of ADRs is encouraged at many levels.
READ MORE
Ecopharmacovigilance
The environmental damage caused by the improper disposal and spillage of medicines is currently considered a major problem. However, there is no adequate measurement of the impact and scope of this problem on public health and the environment.
READ MOREDrug Safety in Older Patients
At ISoP 2018 Annual Meeting in Geneva, a very successful pre-conference course on Drug Safety in Older Patients was organized. Some of the course speakers realized the topic was a neglected but very important field that required further development.
READ MORE
Real-World Evidence and Big Data Group
Big data are defined as “extremely large datasets that may be complex, multi-dimensional, unstructured heterogeneous and which are accumulating rapidly and may be analyzed computationally to reveal patterns, trends, and associations”.
READ MORE